The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TRANSFORMER: Bipolar androgen therapy (BAT) versus enzalutamide (E) for castration-resistant metastatic prostate cancer (mCRPC).
 
Samuel R. Denmeade
Stock and Other Ownership Interests - Sophiris Bio
Consulting or Advisory Role - Sophiris Bio
Travel, Accommodations, Expenses - Sophiris Bio
 
Hao Wang
No Relationships to Disclose
 
Harry Cao
No Relationships to Disclose
 
Wei Fu
No Relationships to Disclose
 
Ting Wang
No Relationships to Disclose
 
Rehab Abdallah
No Relationships to Disclose
 
Vanessa Bolejack
No Relationships to Disclose
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Foundation Medicine; Foundation One Inc; Janssen Oncology; Lilly; Lilly; Lilly; Medivation/Astellas; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics
Research Funding - Active Biotech (Inst); Amgen (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
David C. Smith
Research Funding - Agensys (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb/Medarex (Inst); ESSA (Inst); Exelixis (Inst); Genentech (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); MedImmune (Inst); Medivation/Astellas (Inst); Merck (Inst); Millendo (Inst); Millennium (Inst); Novartis (Inst); OncoMed (Inst); Roche (Inst); Seagen (Inst)
 
Michael Thomas Schweizer
Consulting or Advisory Role - Janssen
Research Funding - AstraZeneca (Inst); Immunomedics (Inst); Janssen (Inst); Madison Vaccines, Inc. (Inst); Pfizer (Inst); Roche (Inst); Zenith Epigenetics (Inst)
 
Mark N. Stein
Consulting or Advisory Role - Exelixis; Exelixis; Merck Sharp & Dohme
Research Funding - Advaxis (Inst); Bristol-Myers Squibb (Inst); Genocea Biosciences (Inst); Harpoon (Inst); Janssen Oncology (Inst); Lilly (Inst); Medivation/Astellas (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Oncoceutics (Inst); Seagen (Inst); Suzhou Kintor Pharmaceuticals (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst)
 
Vasily J. Assikis
No Relationships to Disclose
 
Thomas W. Flaig
Leadership - Aurora Oncology
Stock and Other Ownership Interests - Aurora Oncology
Honoraria - BN ImmunoTherapeutics
Consulting or Advisory Role - GTX
Research Funding - Agensys; Aragon Pharmaceuticals; Astellas Pharma; astrazeneca/MedImmune; Bavarian Nordic; Bristol-Myers Squibb; Dendreon; Exelixis; GTx; Janssen Oncology; La Roche-Posay; Lilly; Medivation; Merck; Novartis; Pfizer; Roche/Genentech; Sanofi; Seagen; Sotio; Tokai Pharmaceuticals
Patents, Royalties, Other Intellectual Property - The University of Colorado has filed 2 patents related in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or licensed at this time.
 
Russell Zelig Szmulewitz
Honoraria - Astellas Pharma
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Exelixis; Janssen Oncology; Merck; Pfizer; Sanofi
Research Funding - Abbvie; Astellas Pharma; Incyte; Janssen Oncology; Macrogenics
Patents, Royalties, Other Intellectual Property - Patent licensed by University of Chicago of which I am co-inventor to Corcept Therapeutics for combination AR/GR inhibition in prostate cancer
Travel, Accommodations, Expenses - Corcept Therapeutics
 
Jeffrey Holzbeierlein
Research Funding - MDxHealth (Inst)
 
Channing Judith Paller
Consulting or Advisory Role - Dendreon; Omnitura
Research Funding - Lilly (Inst)
 
Michael Anthony Carducci
Consulting or Advisory Role - Abbvie; Astellas Pharma; Foundation Medicine; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); pfizer (Inst)
 
Mark Christopher Markowski
Honoraria - Clovis Oncology; Exelixis
 
Mario A. Eisenberger
Leadership - Veru
Stock and Other Ownership Interests - Veru; Veru; Veru; Veru
Honoraria - pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Ipsen; pfizer; Sanofi; Sanofi
Research Funding - Genentech; Sanofi; Tokai Pharmaceuticals
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; Pfizer; Sanofi; Veru
 
Emmanuel S. Antonarakis
Honoraria - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Clovis Oncology; Dendreon; ESSA; Janssen Biotech; Medivation; Merck; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Co-inventor of a biomarker technology that has been licensed to Qiagen
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi